ClinicalTrials.gg

Program

cronexitide lanocianine

Also written as “LS301-IT 0.1 mg/kg”, “LS301-IT 0.025 mg/kg” and “LS301-IT 0.05 mg/kg”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Intraductal, Noninfiltrating · Lung Neoplasms, led by Integro Theranostics.

Furthest: phase 2, since May 10, 20233 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Integro Theranostics31 open or runningphase 2since May 10, 2023May 10, 2023Jun 2027phase 2 · NCT07276789

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2023First study: phase 2 study in Breast NeoplasmsFirst studyNCT05900986 · 22 enrolled · United States
  2. Nov 19, 2024Phase 1 study in Lung NeoplasmsNCT06713564 · 24 enrolled · United States
  3. Dec 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07276789 · 35 enrolled · United States

Ahead

  1. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07276789

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07276789Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingJun 202735
NCT06713564Lung Neoplasms · United States1CompletedMay 6, 202624
NCT05900986Breast Neoplasms · United States2CompletedOct 6, 202522

How it is read

Names in the registry

  • “LS301-IT 0.1 mg/kg”, 2 entries
  • “LS301-IT 0.025 mg/kg”, 1 entry
  • “LS301-IT 0.05 mg/kg”, 1 entry
  • “LS301-IT 0.075 mg/kg”, 1 entry
  • “LS301-IT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.